Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

0.88USD
15 Dec 2017
Change (% chg)

$0.02 (+2.90%)
Prev Close
$0.85
Open
$0.87
Day's High
$0.88
Day's Low
$0.85
Volume
22,007
Avg. Vol
26,728
52-wk High
$4.95
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 04:45pm EDT 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017
Monday, 28 Aug 2017 04:50pm EDT 

Aug 28 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​.InVivo Therapeutics Holdings Corp says ‍restructuring is expected to extend company's cash runway into beginning of Q3 of 2018 - SEC filing​.InVivo Therapeutics Holdings - ‍expects restructuring will result in total restructuring charges of about $810,000-$1.1 million during year ending Dec 31, 2017.InVivo Therapeutics Holdings-on Aug 28, co notified Thomas Ulich, co's chief scientific officer,that his employment to be terminated effective Aug 30, 2017​.  Full Article

Invivo Therapeutics reports strategic corporate restructuring
Monday, 28 Aug 2017 04:30pm EDT 

Aug 28 (Reuters) - Invivo Therapeutics Holdings Corp ::Invivo Therapeutics announces strategic corporate restructuring.Invivo Therapeutics - ‍company is undergoing a reduction in force (rif), in which it is eliminating 13 positions, or approximately 39 pct of its workforce​.Invivo Therapeutics - ‍company is evaluating strategic options for allowing cell and gene therapy programs to move forward outside of company​.Invivo Therapeutics Holdings Corp - ‍plans to restart cervical study once FDA approves a protocol that allows for enrollment in united states​.Invivo Therapeutics Holdings- ‍as part of decision to focus on inspire, announced suspension of chronic sci stem cell, gene therapy research programs​.Invivo Therapeutics- ‍as part of decision to focus on inspire, also announced halt in enrollment into canadian cervical study of neuro-spinal scaffold​.Invivo Therapeutics Holdings - ‍restructuring actions all together are projected to result in 2018 operating expense savings of approximately $7.3 million​.Invivo Therapeutics Holdings -restructuring actions all together projected to reduce 2018 cash burn from about $2.0 million/month to about $1.5 million/month.  Full Article

InVivo Therapeutics Holdings Q2 adjusted loss per share $0.22 excluding items
Tuesday, 8 Aug 2017 06:00pm EDT 

Aug 8 (Reuters) - Invivo Therapeutics Holdings Corp :InVivo Therapeutics Holdings provides business update and reports 2017 second quarter financial results.Q2 adjusted loss per share $0.22 excluding items.Q2 loss per share $0.20.InVivo Therapeutics Holdings - ‍company ended quarter with $21.8 million of cash, cash equivalents, and marketable securities​.  Full Article

Invivo Therapeutics announces positive resultsin the study of the neuro-spinal Scaffold
Wednesday, 28 Jun 2017 08:00am EDT 

June 28 (Reuters) - Invivo Therapeutics Holdings Corp :Invivo Therapeutics announces positive motor recovery assessments in two patients in the inspire study of the neuro-spinal Scaffold.Continued improvement from AIS B to AIS C for two patients with early conversions.  Full Article

Invivo Therapeutics reports Q1 loss per share $0.20
Thursday, 4 May 2017 04:36pm EDT 

May 4 (Reuters) - Invivo Therapeutics Holdings Corp :Invivo Therapeutics provides clinical update and reports 2017 first quarter financial results.Q1 adjusted loss per share $0.21 excluding items.Q1 loss per share $0.20.  Full Article

Invivo Therapeutics appoints Christopher Mcnulty as CFO
Wednesday, 29 Mar 2017 08:00am EDT 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics appoints Christopher Mcnulty as chief financial officer . Mcnulty will be taking over for interim CFO, Melanie Morel-Ferris .Melanie Morel-Ferris will remain as company's senior director, finance and controller.  Full Article

Invivo Therapeutics receives investigational testing authorization from Health Canada
Thursday, 23 Mar 2017 08:00am EDT 

Invivo Therapeutics Holdings Corp : Receives investigational testing authorization from Health Canada to conduct cervical spinal cord injury study .Currently in late stage conversation with several site research ethics boards; expects to announce first Canadian site in coming weeks.  Full Article

Invivo Therapeutics reports FDA submission
Tuesday, 21 Mar 2017 08:00am EDT 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics announces submission to the FDA of its nonclinical studies module for the neuro-spinal scaffold(tm) . Expect to receive acceptance of nonclinical module in q3 of this year .Plan to submit manufacturing module in second half of 2017 and clinical module in 2018.  Full Article

Invivo Therapeutics receives clinical trial application approval from UK's MHRA
Wednesday, 15 Mar 2017 08:00am EDT 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics receives clinical trial application approval from UK's Medicines Healthcare Products Regulatory Agency .Invivo Therapeutics Holdings - currently in late-stage conversation with various clinical sites, first UK site opening should occur in coming weeks.  Full Article

Deals of the day-Mergers and acquisitions

Nov 10 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday: